[ELAN] Elanco Animal Health Thesis 2026: Companion Animal Innovation Drives Farm Animal Cycle Recovery

Key Takeaways

• ELAN FY2025 revenue ~$4.45-4.65B (+1-5% YoY) with adj. EPS ~$0.92-1.10 reflecting continued post-2024 ~$2.30-2.45B aggregate Pet Health revenue (~52% aggregate revenue mix; selected primary Companion Animal innovation + selected various Credelio Quattro + Zenrelia + Bovaer launches) + selected continued post-2024 ~$2.10-2.25B aggregate Farm Animal revenue (~48% aggregate revenue mix; selected primary Cattle + Poultry + Aqua + Swine production animal health) under continued President + CEO Jeff Simmons since 2018 (~7-year tenure as Elanco CEO; selected post-2018 Eli Lilly spinoff).
• Companion animal innovation cycle (Credelio + Zenrelia + Bovaer): ~$2.30-2.45B Pet Health revenue (~52% revenue mix); selected post-July 2024 Credelio Quattro (broad-spectrum parasiticide) FDA approval + selected post-September 2024 Zenrelia (atopic dermatitis JAK inhibitor) FDA approval + selected post-November 2024 Bovaer (methane reducer) US launch; selected projected ~$300-500M aggregate cumulative innovation portfolio peak revenue.
• Farm animal cycle recovery + post-2020 Bayer Animal Health integration: ~$2.10-2.25B Farm Animal revenue (~48% revenue mix); selected continued post-2020 ~$7.6B+ Bayer Animal Health acquisition integration; selected continued post-2024 selected various US poultry + cattle + swine + aqua aggregate cycle recovery; selected various ~3-5% aggregate organic Farm Animal growth.
• Capital return + deleveraging: ~$0 dividend (no dividend track post-2018 NYSE IPO); minimal opportunistic buybacks; aggregate capital return ~$0-50M FY2025; ~$0.4-0.5B aggregate cash + investments balance; net leverage ratio ~5.0-5.5x net debt-to-adj. EBITDA (selected continued post-2020 Bayer Animal Health acquisition leverage); selected post-2024 ~$0.5-0.7B aggregate annual debt paydown; investment-grade B1/BB credit rating (selected continued post-2020 below investment grade post-Bayer leverage).
• FY2026 thesis catalysts: Companion animal innovation cycle (Credelio Quattro + Zenrelia + Bovaer) + Farm animal cycle recovery + selected post-2020 Bayer Animal Health integration + selected ~$0.5-0.7B aggregate annual debt paydown + selected projected post-2027 investment-grade upgrade.

Company Background

Elanco Animal Health Inc. (NYSE: ELAN) is one of the largest US + global Companion Animal + Farm Animal health companies, founded 1954 as Elanco division of Eli Lilly + Co. in Greenfield Indiana (71-year heritage; selected pioneer animal health veterinary products). Selected post-September 2018 NYSE IPO ($1.7B aggregate IPO proceeds) following ~$5B+ Eli Lilly spinoff; selected post-July 2020 ~$7.6B+ Bayer Animal Health acquisition + selected various integration; selected post-2018-2024 ~$15B+ aggregate cumulative platform expansion (selected post-2018-2024 selected various Aratana Therapeutics + Prevtec Microbia + selected various tuck-in M&A); selected post-July 2024 selected various Credelio Quattro (broad-spectrum parasiticide) FDA approval + selected post-September 2024 Zenrelia (atopic dermatitis JAK inhibitor) FDA approval + selected post-November 2024 Bovaer (methane reducer) US launch; selected post-2018 Jeff Simmons CEO appointment (selected continued post-2018 Eli Lilly spinoff CEO); HQ Greenfield Indiana; ~9,000+ employees globally.

ELAN operates 2 primary business segments: Pet Health (Companion Animal) 52% revenue ($2.30-2.45B — selected primary Companion Animal parasiticides + dermatology + therapeutics + selected various Bayer Companion Animal integration + Credelio Quattro + Zenrelia + Seresto + Galliprant + Trifexis + selected various) + Farm Animal 48% revenue ($2.10-2.25B — selected primary Cattle + Poultry + Aqua + Swine production animal health + selected various Bayer Farm Animal integration + Bovaer + Rumensin + selected various). Geographic mix: US 50%+ revenue ($2.30-2.40B; selected primary US Companion Animal + Farm Animal commercial) + International 50% ($2.15-2.25B; selected primary EU + Latin America + Asia + Australia).

Capital return: ~$0 dividend (no dividend track post-2018 NYSE IPO); minimal opportunistic buybacks; aggregate capital return ~$0-50M FY2025; ~$0.4-0.5B aggregate cash + investments balance; net leverage ratio ~5.0-5.5x net debt-to-adj. EBITDA; selected ~$0.5-0.7B aggregate annual debt paydown; B1/BB credit rating.

Companion Animal Innovation Cycle (Credelio + Zenrelia + Bovaer)

The companion animal innovation cycle is ELAN's foundation thesis: ~$2.30-2.45B Pet Health revenue (~52% revenue mix) + selected post-July 2024 Credelio Quattro (broad-spectrum parasiticide; oral chewable; lotilaner + moxidectin + praziquantel + pyrantel) FDA approval + selected post-September 2024 Zenrelia (atopic dermatitis JAK inhibitor; ilunocitinib oral tablet) FDA approval + selected post-November 2024 Bovaer (methane reducer; 3-NOP) US launch + selected projected ~$300-500M aggregate cumulative innovation portfolio peak revenue.

FY2025 Pet Health dynamics ($2.30-2.45B aggregate Pet Health revenue): selected continued post-2024 ~$300-450M aggregate Credelio Quattro + Zenrelia + Bovaer initial launch revenue + selected various Companion Animal + selected various Bayer Companion Animal integration + selected various Seresto + Galliprant + Trifexis + selected various existing portfolio. Selected post-2024 ~$0.30-0.50 incremental annual EPS contribution as Companion Animal innovation cycle (Credelio Quattro + Zenrelia + Bovaer launches) drives incremental margin + Pet Health revenue.

FY2026 catalyst: continued companion animal innovation cycle + ~$0.30-0.50 incremental annual EPS contribution under continued President + CEO Jeff Simmons leadership (~7-year tenure). Selected aggregate ~$2.40-2.60B aggregate Pet Health revenue + selected various Credelio Quattro + Zenrelia + Bovaer launch trajectory + selected various ~$500-700M aggregate cumulative innovation portfolio revenue. Risks: Zoetis + Boehringer Ingelheim + Merck Animal Health (MSD) + Virbac + selected various global animal health + selected various aggregate companion animal competitive displacement + selected post-2024 Credelio Quattro + Zenrelia + Bovaer launch slower-than-expected.

Farm Animal Cycle Recovery + Post-2020 Bayer Animal Health Integration

The farm animal cycle recovery + post-2020 Bayer Animal Health integration is ELAN's primary growth thesis: ~$2.10-2.25B Farm Animal revenue (~48% revenue mix) + selected continued post-2020 ~$7.6B+ Bayer Animal Health acquisition integration + selected continued post-2024 selected various US poultry + cattle + swine + aqua aggregate cycle recovery + selected various ~3-5% aggregate organic Farm Animal growth + selected post-November 2024 Bovaer (methane reducer; 3-NOP) US launch.

FY2025 Farm Animal dynamics: ~$2.10-2.25B aggregate Farm Animal revenue + selected various Cattle + Poultry + Aqua + Swine production animal health + selected various Bayer Farm Animal integration + selected various Bovaer + Rumensin + selected various legacy portfolio. Selected post-2024 ~$0.10-0.20 incremental annual EPS contribution as Farm Animal cycle recovery + selected post-2020 Bayer Animal Health integration drives incremental margin + Farm Animal revenue.

FY2026 catalyst: continued Farm Animal cycle recovery + ~$0.10-0.20 incremental EPS contribution. Selected aggregate ~$2.15-2.30B aggregate Farm Animal revenue + selected ~3-5% aggregate organic Farm Animal growth + selected various Bovaer methane reducer launch trajectory + selected various US poultry + cattle + swine + aqua cycle recovery. Risks: Zoetis + Boehringer Ingelheim + Merck Animal Health (MSD) + Virbac + selected various global animal health + selected various aggregate Farm Animal competitive displacement + Farm Animal cycle (selected various US Cattle + Poultry + Swine + Aqua aggregate cycle).

Capital Return + Deleveraging

Capital return + deleveraging: ~$0 dividend (no dividend track post-2018 NYSE IPO) + minimal opportunistic buybacks + aggregate capital return ~$0-50M FY2025 + ~$0.4-0.5B aggregate cash + investments balance + net leverage ratio ~5.0-5.5x net debt-to-adj. EBITDA (selected continued post-2020 Bayer Animal Health acquisition leverage) + selected post-2024 ~$0.5-0.7B aggregate annual debt paydown + B1/BB credit rating + selected projected post-2027 investment-grade upgrade.

FY2026 catalyst: continued ~$0.5-0.7B aggregate annual debt paydown + selected continued ~5.0-5.5x → ~4.5-5.0x net leverage trajectory + selected projected post-2027 investment-grade upgrade. Selected aggregate ~$0.5-0.7B aggregate annual debt paydown + selected continued post-2020 Bayer Animal Health acquisition deleveraging + selected projected post-2027 investment-grade upgrade support continued ELAN compounding profile.

Key Core Metrics

• FY2025 revenue ~$4.45-4.65B (+1-5% YoY) vs $4.42B FY2024; adj. EPS ~$0.92-1.10
• 2 segments: Pet Health (Companion Animal) ~52% ($2.30-2.45B), Farm Animal ~48% ($2.10-2.25B)
• Geographic mix: US ~50%+ + International ~50%
• Companion Animal innovation: Credelio Quattro (post-July 2024 FDA approval) + Zenrelia (post-September 2024 FDA approval) + Bovaer (post-November 2024 US launch)
• ~$300-500M aggregate cumulative innovation portfolio peak revenue
• ~480-500M diluted shares; ~$0-50M total capital return FY2025
• ~$0 dividend (no dividend track post-2018 NYSE IPO)
• ~$0.4-0.5B aggregate cash + investments balance
• Net leverage ratio ~5.0-5.5x net debt-to-adj. EBITDA
• ~$0.5-0.7B aggregate annual debt paydown
• B1/BB credit rating (below investment grade post-Bayer leverage)
• President + CEO Jeff Simmons (since 2018); CFO Todd Young

Market Evaluation

ELAN trades as a Companion Animal + Farm Animal health company levered to companion animal innovation cycle (Credelio Quattro + Zenrelia + Bovaer) + Farm Animal cycle recovery + selected post-2020 Bayer Animal Health integration + selected post-2024 deleveraging trajectory. Bull case: ~$2.30-2.45B Pet Health + ~$2.10-2.25B Farm Animal + Credelio Quattro + Zenrelia + Bovaer launches + ~$300-500M innovation portfolio peak revenue + selected ~$0.5-0.7B annual debt paydown + selected projected post-2027 investment-grade upgrade drive ~$1.10-1.30 adj. EPS FY2026 (+15-20% YoY). Bear case: Zoetis + Boehringer Ingelheim + Merck Animal Health (MSD) + Virbac competitive displacement + Credelio Quattro + Zenrelia + Bovaer launch slower-than-expected + Farm Animal cycle severe + selected post-2020 Bayer Animal Health integration considerations + sustained ~5.0-5.5x net leverage trigger material EPS compression. Base case: Companion animal innovation cycle + Farm animal cycle recovery + selected post-2020 Bayer integration + ~$0.5-0.7B annual debt paydown support continued ~$1.10-1.30 adj. EPS FY2026.

Companion Animal Innovation Drives Farm Animal Cycle Recovery Deep Dive

Selected continued post-2024 ~$2.30-2.45B aggregate Pet Health revenue (~52% revenue mix; selected primary Companion Animal innovation + Bayer integration) + selected continued post-2024 ~$2.10-2.25B aggregate Farm Animal revenue (~48% revenue mix; selected primary Cattle + Poultry + Aqua + Swine + selected post-2020 Bayer Animal Health integration) + selected continued post-July 2024 Credelio Quattro (broad-spectrum parasiticide) FDA approval + selected continued post-September 2024 Zenrelia (atopic dermatitis JAK inhibitor) FDA approval + selected continued post-November 2024 Bovaer (methane reducer; 3-NOP) US launch + selected projected ~$300-500M aggregate cumulative innovation portfolio peak revenue + selected continued post-2020 ~$7.6B+ Bayer Animal Health acquisition integration + selected continued post-2024 ~5.0-5.5x net leverage + selected post-2024 ~$0.5-0.7B aggregate annual debt paydown + selected projected post-2027 investment-grade upgrade drive ELAN's primary FY2026 thesis. President + CEO Jeff Simmons (~7-year tenure) leadership continues post-2018 CEO appointment focus on Companion animal innovation cycle + Farm animal cycle recovery + Bayer Animal Health integration + deleveraging discipline. Risks: Zoetis + Boehringer Ingelheim + Merck Animal Health (MSD) + Virbac + selected various global animal health + selected various aggregate Companion Animal + selected various aggregate Farm Animal + selected various aggregate competitive displacement + Credelio Quattro + Zenrelia + Bovaer launch slower-than-expected + Farm Animal cycle (selected various US Cattle + Poultry + Swine + Aqua aggregate cycle) + selected post-2020 Bayer Animal Health integration considerations + sustained ~5.0-5.5x net leverage + selected projected post-2027 investment-grade upgrade timing considerations + selected post-2018 Eli Lilly spinoff legacy + selected post-2018-2024 ~$15B+ aggregate cumulative platform expansion integration considerations.